For the first time, Dishman Carbogen Amcis Ltd participated in the Pharmtech & Ingredients, Crocus Expo, Eurasia, in Moscow. DCAL was represented by Saleem Shaikh, General Manager, Marketing. The expo was the perfect platform for DCAL to connect with prospective customers and partners from the Russian and CIS regions. Our softgels portfolio received particular interest from visitors in addition to our API and CRAMS showcase.
Our team visited CpHI Milan 2024 held from 8-10 October at the Fiera Milano in Italy. As every year at the various editions of the CpHI all over the world, it was wonderful to connect with new and existing customers through engaging conversations. We look forward to our interactions culminating into new possibilities, innovations, and solutions to enhance and support the healthcare and pharmaceutical industry.
New Delhi, INDIA (August 28 - 30, 2024) - We were thrilled to showcase our formulation business portfolio at India's most prestigious global pharmaceutical exhibition, the iPHEX 2024. Our team exhibited our key strengths in soft gel formulations comprising superior products catering to emerging health and wellness needs. They also gave customers an extensive overview of our core capabilities in Contract Research Manufacturing (CRM), Contract Development and Manufacturing (CDM), Contract Research (CRO), etc.
We had the pleasure of meeting customers and visitors from all over the globe. It was a great opportunity for our team to communicate to a global audience about our unmatched capabilities in the formulation business. iPHEX 2024 was the perfect platform to showcase DCAL's entry into, and capabilities in, soft gel capsule formulation and represent our global mega-brand, Dishman Carbogen Amcis Ltd.
This exhibition brings the drugs, pharmaceutical and healthcare industries- all under one roof. It showcases Indian pharmaceutical products and technologies to a global audience. We met focused overseas buyers and new and existing customers looking for new opportunities in the soft gel capsules formulations market. Our team met 50+ overseas buyers and more than 100 Indian pharma professional visitors. Key customers from different regions expressed great interest in being associated with us.
Africa Continent - Nigeria, Kenya, Tanzania, Ghana, Sierra Leone, Burkina Faso, Rwanda, South Africa, St. Lucia, Guyana, etc.
South East Asia – Philippines, Cambodia, Myanmar, Malaysia, Vietnam, India
CIS: Uzbekistan, Turkey, Russia, Siberia, Uzbekistan
Latin & Central America – Guatemala, Peru, Ecuador, Mexico, Bolivia
Others – United Arab Emirates
Speaking about his experience at iPHEX 2024 and business prospects, Mr. Badarinarayan Herur, Head - Formulations, Dishman Carbogen Amcis Ltd said:
“Soft gelatin capsule formulations have a bright future. We have received multiple enquiries for CRAMS opportunities in soft gel capsule formulations. The CRAMS market demand is high due to the scarcity of skilled quality players in this formulation segment. The core strengths of DCAL are its science-based approach towards product development, regulatory-sufficiency documentation with an international standard manufacturing facility, and support staff with in-depth technical knowledge and experience in soft gel capsules technical know-how. Our core development strength is converting very poorly soluble API into soft gel formulation to enhance bioavailability.
As a new entrant in the soft gel capsule formulation business, we keep working towards the diversification of product portfolios in different therapeutic ranges with a scientific approach. With a wide diversified range of products, we want our customers to meet the market needs and demands. At iPHEX, we were proud to connect with overseas buyers and Indian visitors who are familiar with the Dishman brand in the API business. They were very impressed with our venture into the very niche formulation category of soft gelatin capsule dosage forms CRAMS business.”
NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new state-of-the-art facility in Saint Beauzire, France, and the increase in Human Capital over the last few years.
Giving a detailed overview of the company's facility in Saint Beauzire and future business plans, Mr. Harshil Dalal, Group CFO - Dishman Group, stated:
“We thank the Indo French Chamber of Commerce and Industry for this wonderful recognition of our efforts to make France our destination of choice to do business."
Dishman Carbogen Amcis Ltd stands as a beacon of innovation and progress in the healthcare industry, transcending borders with our multi-site transcontinental presence. With 11 manufacturing sites and 6 sales offices spread across 6 countries, and subsidiaries in key regions like Switzerland, France, Netherlands, UK, and China, we're poised to deliver comprehensive healthcare solutions like never before.
Our journey in France epitomizes our commitment to growth and excellence. In 2012, we acquired a small but promising company, igniting a transformative journey in the realm of Sterile Investigational Medicinal Products (IMPS). Specializing in complex compounds, this facility became a nucleus for innovation, crafting aseptic drug products for preclinical and clinical batches in various forms.
Fast forward to 2023, a milestone year as we inaugurated our state-of-the-art facility in Saint Beauzire. With a Euro 58 million investment, this cutting-edge 9500 m2 establishment symbolizes our dedication to pushing boundaries. Operational since October 2023, it hosts over 100 skilled professionals, a testament to our commitment to job creation and skill development.
Our growth trajectory is not just about numbers; it's about impact. From a modest headcount of 34 in 2018-19, we've surged to 120 by March 2024, with sights set on reaching 200 by March 2028. This expansion isn't just about revenue; it's about societal contribution. From Euro 5 million annually to a projected Euro 40 million, our growth isn't just corporate—it's communal.
Beyond financial gains, our France site embodies potential. It's a gateway to new markets, a hub for R&D, and a catalyst for groundbreaking therapies like anti-cancer drugs. As we expand, so does our organizational backbone, with 70 new positions created, heralding a future brimming with opportunities.
Reflecting on our journey, we've come a long way from our humble beginnings. Yet, amidst our growth, the most profound transformation is the confidence we hold in the future—a future shaped by relentless innovation, unwavering dedication, and boundless potential."
Gujarat, India - After a successful on-site inspection, Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) certification.
DCAL’s drug substances manufacturing facility located in Bavla, underwent an inspection by the Japanese Health Authority. We are glad to announce that the inspection ended satisfactorily, and no major or critical observations were reported. As a result, PMDA recently awarded the company with the certification of GMP compliance. We are proud of this achievement which is an acknowledgement of our efforts toward maintaining current Good Manufacturing Practices (cGMPs). This certification reaffirms our commitment to improving the health of people all over the world.
We take this opportunity to heartily congratulate our teams and laud their sincerity and dedication that led to this positive outcome.
Speaking about the PMDA certification, here is what our COO, Mr. Paolo Armanino, said: “First of all, we would like to thank PMDA for their time and invaluable feedback. We feel proud to continue to be approved by the Japanese Authority. I would also like to extend my heartfelt congratulations to all the team who made this remarkable achievement possible.
We maintain strategic ties with our Japanese customers, and we recognize the company's responsibility to work closely together to improve patient health and safety. Dishman Carbogen Amcis Ltd supplies several critical drugs to the Japanese market, and we see several significant and positive developments in our business in the upcoming years.
Going forward, we aim to further expand our services and products portfolio in Japan to fulfil the customer’s needs. In order to closely engage with the demands and requirements of the Japanese market, we are thrilled to be visiting Tokyo in a few weeks for CPHI Japan, and look forward to meeting our existing and prospective valuable customers and partners.
Read more …DCAL's Bavla plant gets PMDA approval
“Dishman Group” is not a separate legal entity but nomenclature used in generality for Dishman Carbogen Amcis Ltd, the flagship Company, and its Indian and foreign subsidiaries, joint ventures and associate companies across the globe. All these entities are individual and separate by the law.
